R Squared’s Exagen XGN Stock Holding History

R Squared’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$176K	Sell	21,649 -4,424	-17%	-$28.4K	0.09%	353
2026 Q2	$121K	Sell	26,073 -1,034	-4%	-$3.89K	0.06%	388
2026 Q1	$81.3K	Buy	27,107 +8,915	+49%	+$34.5K	0.04%	384
2025 Q4	$111K	Buy	+18,192	New	+$166K	0.05%	402

Other funds holding XGN

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $33.5B AUM 25.57% 1-Year Est. Return

Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

R Squared's XGN Position: Q3 2026 in Review

R Squared reduced its Exagen (XGN) stake by 17% in Q3 2026, selling an estimated $28.4K and leaving 21,649 shares worth $176K. The position accounts for 0.09% of the portfolio, ranked #353.

R Squared first reported a position in XGN in Q4 2025 and has held it in 4 quarters since. 15 funds tracked by Wall St. Rank hold XGN as of Q3 2026.

R Squared held 21,649 shares of Exagen worth $176K as of Q3 2026.
R Squared sold 4,424 Exagen shares in Q3 2026, an estimated $28.4K.
Exagen made up 0.09% of R Squared's portfolio in Q3 2026, its #353 holding.
R Squared first reported a position in Exagen in Q4 2025 and has held it in 4 quarters since.
15 funds tracked by Wall St. Rank held Exagen as of Q3 2026.

Based on R Squared's 13F filing for Q3 2026, filed 6 Nov 2026.